Does Rallies show Form 4 insider transactions for NMRA?

Yes. Rallies tracks NMRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NMRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NMRA. It does not provide personalized investment advice.

NMRA (Neumora Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Neumora Therapeutics, Inc. Common Stock (NMRA) is a publicly traded Healthcare sector company. As of May 21, 2026, NMRA trades at $1.78 with a market cap of $327.95M and a P/E ratio of -1.18. NMRA moved +3.59% today. Year to date, NMRA is +5.20%; over the trailing twelve months it is +135.71%. Its 52-week range spans $0.61 to $17.19. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces NMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NMRA stock inside the company?

Recent NMRA insider activity includes Aurora Daljit Singh sold 6.17K, Pinto Joshua sold 5.97K, BERNS PAUL L sold 9.82K, Milligan Michael Lee sold 1.44K, and Aurora Daljit Singh sold 114.70K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NMRA Key Metrics

Key financial metrics for NMRA
Metric	Value
Price	$1.78
Market Cap	$327.95M
P/E Ratio	-1.18
EPS	$-1.45
Dividend Yield	0.00%
52-Week High	$17.19
52-Week Low	$0.61
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-236.93M
Gross Margin	0.00%

Recent NMRA Insider Trades

Aurora Daljit Singh sold 6.17K (~$21.92K) on Feb 17, 2026.
Pinto Joshua sold 5.97K (~$21.09K) on Feb 17, 2026.
BERNS PAUL L sold 9.82K (~$34.46K) on Feb 17, 2026.
Milligan Michael Lee sold 1.44K (~$5.12K) on Feb 17, 2026.
Aurora Daljit Singh sold 114.70K (~$307.03K) on Nov 11, 2025.

Latest NMRA News

Neumora Q1 Cash $147.1M, KOASTAL-2/3 Readout Slated Q2 2026 — May 7, 2026
Neumora Secures $182.5M Cash Runway, KOASTAL-2/3 Fully Enrolled and NMRA-511 Effect Sizes — Mar 30, 2026
Neumora Sees 20-Point CMAI Reduction for NMRA-511, Targets Higher Doses in 2026 — Feb 14, 2026

NMRA Analyst Consensus

7 analysts cover NMRA: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.

Common questions about NMRA

Who is trading NMRA stock inside the company?: Recent NMRA insider activity includes Aurora Daljit Singh sold 6.17K, Pinto Joshua sold 5.97K, BERNS PAUL L sold 9.82K, Milligan Michael Lee sold 1.44K, and Aurora Daljit Singh sold 114.70K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NMRA?: Yes. Rallies tracks NMRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NMRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NMRA. It does not provide personalized investment advice.